To meet growing industry needs for AAV, we have developed the VirusExpress® 293 AAV production platform and established an upstream process for AAV manufacturing. It utilizes a suspension-adapted cell line in chemically defined media using plasmid based, transient transfection. We have advanced the platform by utilizing a high-throughput automated microbioreactor system and a DOE approach. Improvements have been made to the transfection process and cell culture media. Join our webinar to learn how to speed through AAV manufacturing.
In this webinar, you will learn:
Head of R&D for Viral Vector Producer Cell Lines
Since 1981, Henry has worked in both the biotechnology and pharmaceutical sectors, developing protein expression systems in bacterial, insect, and mammalian hosts. He joined our company in 2001 as an R&D manager, and currently leads a viral vector producer cell lines R&D group.
Scientist, Viral Vector Technology and Innovation
Andi Ushijima is a scientist in the viral vector innovation and technology group at MilliporeSigma. She has a lot of experience with upstream bioprocessing, working on bioreactor development and scale-up of monoclonal antibodies, virus-like particles, and viral vectors. She received her B.S. in bioengineering at UCSD.
To continue reading please sign in or create an account.Don't Have An Account?